Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (9)

2022

  1. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83

2018

  1. Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279

2017

  1. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial

    Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301

  2. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

    Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402

  3. Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease

    Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800

  4. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

2016

  1. Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study

    American Journal of Gastroenterology, Vol. 111, Núm. 2, pp. 261-268

  2. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab

    Biochemical Pharmacology, Vol. 122, pp. 33-41

  3. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort

    Inflammatory Bowel Diseases, Vol. 22, Núm. 7, pp. 1662-1669